Cargando…
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
The CHL1 gene encodes a cell-adhesion molecule proposed as being a putative tumour-suppressor gene in breast cancer (BC). However, neither the underlying molecular mechanisms nor the clinical value of CHL1 downregulation in BC has been explored. The methylation status of three CpG sites in the CHL1...
Autores principales: | Martín-Sánchez, Esperanza, Mendaza, Saioa, Ulazia-Garmendia, Ane, Monreal-Santesteban, Iñaki, Blanco-Luquin, Idoia, Córdoba, Alicia, Vicente-García, Francisco, Pérez-Janices, Noemí, Escors, David, Megías, Diego, López-Serra, Paula, Esteller, Manel, Illarramendi, José Juan, Guerrero-Setas, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362523/ https://www.ncbi.nlm.nih.gov/pubmed/28178655 http://dx.doi.org/10.18632/oncotarget.15004 |
Ejemplares similares
-
CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
por: Martín-Sánchez, Esperanza, et al.
Publicado: (2017) -
A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis
por: Mendaza, Saioa, et al.
Publicado: (2021) -
ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer
por: Mendaza, Saioa, et al.
Publicado: (2020) -
Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis
por: Perez-Janices, Noemi, et al.
Publicado: (2015) -
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
por: Escors, David, et al.
Publicado: (2013)